Conditions: Dyslipidemias Coronary Heart Disease Combined (Atherogenic) Dyslipidemia Mixed Dyslipidemia
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 543
Healthy volunteers: no

Brief summary:
The primary purpose of this study is to compare the safety and efficacy of ABT-335 (investigational drug) coadministered with atorvastatin and ezetimibe to atorvastatin coadministered with ezetimibe in subjects with abnormal lipid (fat) levels in the blood.

Detailed description:

Arms:
arm 1: None arm 2: None

Interventions: intervention 1: ABT-335 intervention 2: placebo intervention 3: atorvastatin intervention 4: ezetimibe
Intervention descriptions: intervention 1: 135 mg capsule, daily, 12 weeks intervention 2: placebo capsule, daily, 12 weeks intervention 3: 40 mg, tablet, daily, 12 weeks intervention 4: 10 mg capsule, daily, 12 weeks

Protocol document: